The tumor microenvironment is a complex mix of cancer cells, immune cells, and other components that all play a part in tumor progression, metastasis, and therapy responses. Understanding the highly ...
A phase 1/2 study of FOG-001, a first-in-class direct β-catenin: TCF inhibitor, in patients with colorectal cancer (CRC) and other locally advanced or metastatic solid tumors. This is an ASCO Meeting ...